Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [68Ge]Ge/[68Ga]Ga Generators: Fractional Elution or Prepurification?

Author:

Durieux Flore12,Dekyndt Bérengère123,Legrand Jean-François12ORCID,Rogeau Antoine2ORCID,Malek Emmanuel4,Semah Franck25,Odou Pascal13

Affiliation:

1. Institute of Pharmacy, CHU Lille, F-59000 Lille, France

2. Nuclear Medicine Department, CHU Lille, F-59000 Lille, France

3. EA 7365-GRITA—Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, F-59000 Lille, France

4. Radiopharmacy Unit—Institute of Pharmacy, CH Valenciennes, F-59300 Valenciennes, France

5. Inserm U1171, University of Lille, F-59000 Lille, France

Abstract

Prostate cancer is one of the most common forms of cancer in men. An imaging technique for its diagnosis is [68Ga]-prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) positron emission tomography (PET). To address the increasing demand for [68Ga]-labeled peptides and reduce the cost of radiosynthesis, it is therefore necessary to optimize the elution process of [68Ge]Ge/[68Ga]Ga generators. This study aims to identify the most effective approach for optimizing radiosynthesis using double elution in parallel of two [68Ge]Ge/[68Ga]Ga generators. Two methods have been tested: one using prepurification, and the other using fractionated elution. Five synthesis sequences were conducted using each method. The mean labeling yields for double elution with prepurification were 45.8 ± 29.4 (mean ± standard deviation) and none met the required criteria. The mean labeling yields for the fractionated double elution were 97.5 ± 1.9 (mean ± standard deviation) meeting the criteria, significantly superior to the prepurification method (p = 0.012), and similar to those of simple elution. This study showed that fractionated double elution from [68Ge]Ge/[68Ga]Ga generators produced a significantly higher labeling yield than double elution with prepurification, resulting in a larger activity recovered via radiosynthesis, thereby allowing more diagnostic tests to be performed.

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference12 articles.

1. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers;Dyba;Eur. J. Cancer,1990

2. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann. Oncol.,2020

3. (2023, April 01). Protocole D’utilisation Thérapeutique et de Recueil D’informations PSMA-11 10 µg, Poudre Pour Solution Injectable. Janvier 2022. Available online: https://ansm.sante.fr/uploads/2022/01/10/20220110-aac-psma-11-put-01-22.pdf.

4. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis;Perera;Eur. Urol.,2020

5. [68Ga]Ga-PSMA-11 in prostate cancer: A comprehensive review;Bois;Nucl. Med. Mol. Imaging,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3